128 results about "Neurological Damage" patented technology

The invention relates to the technical field of related drugs for nerve injury caused by heavy metal pollution, in particular to application of a compound for inhibiting phosphorylation of ARMC10 in preparation of drugs for antagonizing tin-induced nervous system injury. Exposure of trimethyltin chloride induces nerve cell mitochondrial dysfunction, and the key mechanism is ARMC10 serine 43 site abnormal phosphorylation. Phosphorylated protein causes excessive mitochondrial fission, membrane potential collapse and energy metabolism disorder, resulting in neuron damage. Based on the target spot, a compound for antagonizing tin-induced nervous system injury is obtained through screening, protein phosphorylation can be specifically inhibited, mitochondrial dynamic unbalance and dysfunction induced by trimethyltin chloride are effectively reversed, and neurotoxicity is relieved. According to the technical scheme, the technical problem that in the prior art, no medicine for effectively antagonizing tin-induced nervous system injury exists can be solved, and the compound has the application potential for treating the nervous system injury and cognitive impairment caused by tin exposure.

The invention relates to the field of remote quality control of kinesio, and provides a remote kinesio treatment guidance and quality control system. The image acquisition module is used for acquiring high-definition image data of a to-be-treated area through intelligent terminal equipment and marking anatomical feature points; wherein the high-definition image data comprises a static image and a dynamic muscle movement video stream; the AI analysis engine is used for carrying out feature extraction on the high-definition image data based on a muscle dynamics model of a to-be-treated region constructed by a convolutional neural network, identifying a muscle tension abnormal region and grading a nerve injury degree, and generating an initial sticking path recommendation scheme; the remote auditing interface transmits the recommended scheme generated by the AI to the doctor end interaction interface, obtains a target treatment scheme after the doctor end performs scheme correction based on the medical history data of the patient, and confirms a final treatment instruction through a digital signature; and the block chain quality control module is used for encrypting key operation data in the treatment process and then writing the key operation data into a distributed account book to generate a treatment process traceability chain which cannot be tampered.

The invention belongs to the technical field of microorganisms, and relates to lactobacillus acidophilus LA4 and application thereof. The classification name of the lactobacillus acidophilus LA4 is lactobacillus acidophilus, the lactobacillus acidophilus LA4 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on July 9, 2025, and the preservation number of the lactobacillus acidophilus LA4 is CGMCC No.35144; the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain can significantly improve cognitive impairment of an elderly behavior cognitive impairment model mouse and enhance the learning and memory ability of the mouse by reducing deposition of beta amyloid protein in the brain of the mouse, inhibiting the activity of acetylcholin esterase, regulating and controlling the neurotransmitter level, relieving brain inflammatory response, reducing nerve injury, promoting synaptic regeneration and the like. The strain provided by the invention provides a potential treatment scheme for preventing or improving senile behavioral cognitive impairment, and has important development and application values.

The invention discloses a method for inducing dorsal root node satellite glial cells to be reprogrammed into neurons by using a small molecule compound and application of the method. The small molecule compound composition is prepared from ISX-9, RO4929097, CHIR99021, VPA, RepSox, Forskolin, SC79 and VC, and growth factors BDNF, GDNF, NT-3 and NGF beta, neuron culture additives B27 and N2 additives are added at the same time, so that survival and maturation of neurons are promoted and induced. Wherein each component is a safe and low-cost small molecule compound and a neurotrophic factor, and the pharmaceutical composition and the growth factor can be used for reprogramming rat dorsal root ganglion satellite glial cells into neurons with specific phenotypes and functional characteristics in vitro. And a new seed cell is provided for basic research of clinical nerve injury diseases and clinical cell treatment development.

The invention discloses application of an NR1D1 protein phosphorylation site in preparation of cerebral hemorrhage treatment drugs, and belongs to the technical field of molecular biology. According to the invention, the specific phosphorylation site and phosphorylation modification level of the NR1D1 protein are determined for the first time, and the NR1D1 protein can be used as a key marker for evaluating the secondary nerve injury degree of the hemorrhagic cerebral apoplexy and developing treatment and / or alleviation of the hemorrhagic cerebral apoplexy; a specific antigen peptide and an antibody for accurately detecting the NR1D1 protein phosphorylation site are further constructed, and an efficient tool is provided for molecular evaluation of hemorrhagic stroke secondary nerve injury; meanwhile, polypeptide molecules capable of inhibiting NR1D1 protein phosphorylation are researched and developed, through the dual effects of specifically blocking the phosphorylation process and reducing protein degradation, necrosis of brain tissues around hematoma after hemorrhagic cerebral apoplexy is relieved, secondary dyskinesia is improved, and the effect of inhibiting NR1D1 protein phosphorylation is achieved. And a brand new scheme is provided for molecular evaluation and targeted intervention of hemorrhagic stroke secondary nerve injury.

The invention relates to the technical field of intelligent medical prediction, in particular to an intelligent early warning method and system for adverse reactions of chemotherapy medication of tumor patients, and the method comprises the steps: inputting gene sequencing data and time sequence physiological index data of a current patient into a network model, and outputting an injury stage by the network model; the training data set of the network model comprises gene sequencing data, time sequence physiological index data and injury stages; the acquisition process of the injury stage comprises the following steps: acquiring the relative metabolic rate of the gene sequencing data to chemotherapeutics, and further determining the relative speed of in-vivo toxicity accumulation of the gene sequencing data; after time sequence physiological index data of meaningless physiological fluctuation of a historical patient is smoothed, a nerve injury change curve is obtained according to the time sequence physiological index data, whether a potential subclinical signal segment exists in the nerve injury change curve or not is recognized, and if yes, the injury stage is judged according to the potential subclinical signal segment. According to the method, individualized and accurate risk prediction can be carried out before irreversible nerve injury caused by chemotherapy occurs.

The present invention relates to a biomarker composition for diagnosing stroke or post-stroke neurological damage, for diagnosing the severity of stroke or post-stroke neurological damage, and for predicting stroke prognosis, and the like. Using an ischemic stroke mouse disease model, a tissue damage analysis and a behavioral analysis were performed, and the mRNA level expression was confirmed, and as a result, Prox1 or Dcx could be selected as a biomarker. In addition, it was confirmed that the expression of Prox1 or Dcx increased as the severity of stroke or post-stroke neurological damage was higher, and thus the present invention is expected to be useful for diagnosing stroke or post-stroke neurological damage, for diagnosing the severity of stroke or post-stroke neurological damage, and for predicting stroke prognosis.

The utility model discloses a radial artery hemostat with timing and reminding functions, belongs to the technical field of medical auxiliary instruments, and aims to solve the problems that as the radial artery hemostat does not have the timing and reminding functions, nerve injury can occur and the occurrence rate of radial artery occlusion can be increased after the radial artery hemostat compresses the radial artery for a long time. Elastic bands are hinged to the two sides of the fixing plate, a threaded rod is installed at the top end of the fixing plate in a threaded mode, a pressurizing block is rotatably installed at the bottom end of the threaded rod, a screwing head is fixedly installed at the top end of the threaded rod, and installation blocks are fixedly installed at the positions, located on the two sides of the threaded rod, of the top end of the fixing plate; limiting grooves are formed in the opposite sides of the mounting grooves; through the arrangement of the electronic timer and the loudspeaker, medical staff can time conveniently when a patient uses the radial artery hemostat, the use time of the radial artery hemostat can be controlled conveniently, and the situation that the radial artery hemostat is used for a too long time and influences the radial artery of the patient is avoided as much as possible.

This invention relates to a juglansin and lipoic acid conjugate, its preparation method, and its applications. The juglansin and lipoic acid conjugate is named CL-1. CL-1 exhibits significant protective effects in models of oxidative and inflammatory damage in nerve cells, with a significantly greater reduction in TNF-α and IL-6 levels than the monomeric juglansin and lipoic acid, indicating that CL-1 has superior anti-inflammatory and anti-neural damage effects compared to the monomeric drugs, and possesses the potential to treat neurodegenerative diseases such as Alzheimer's disease. The provided preparation method is designed specifically for the structural characteristics of juglansin and lipoic acid, enabling efficient and large-scale synthesis of CL-1.

The invention discloses an aromatic alkylamine ferroptosis inhibitor based on a butylphthalide structure and a preparation method and application thereof. The chemical structural formula of the ferroptosis inhibitor is shown as a formula 1 or a formula 2. The ferroptosis inhibitor can inhibit ferroptosis caused by a ferroptosis inducer and can reduce the level of active oxygen in cells. Nerve injury caused by cerebral ischemia reperfusion can be relieved, and symptoms of neurological diseases such as Alzheimer's disease and Parkinson's disease can be relieved; compared with a ferroptosis inhibitor Ferrostatin-1, the aryl alkyl amine compound disclosed by the invention has better metabolic stability and is suitable for in-vivo drug effect evaluation. Therefore, the novel aryl alkyl amine compound provided by the invention has a very good application value in treatment of neurological diseases related to ferroptosis.

To provide a preventive or improving agent for neurological disorders caused by nerve damage resulting in reduced nerve function.SOLUTION: The preventive or improving agent contains a combination of quinoa or extract thereof and gluconodeltalactone.SELECTED DRAWING: None

The application of CpG oligonucleotides in drugs for diabetic cardiac autonomic neuropathy: Experiments have confirmed that CpG oligonucleotide 1826 can reduce the activation of satellite glial cells in the stellate ganglion and the expression of inflammatory cytokines, inhibit the expression of purine 2Y12 receptors, and reduce lipid peroxidation damage to alleviate ferroptosis in stellate ganglion neurons, thereby improving cardiac autonomic nerve function. Examples of CpG oligonucleotide 1826 demonstrate that CPG-ODN with anti-inflammatory effects or with anti-damage protective effects on the sympathetic nervous system has preventive and therapeutic effects in diabetic cardiac autonomic neuropathy and sympathetic nerve injury-related diseases.

The invention discloses a 2-(piperidinyl) pyridazinone compound (I), pharmaceutically acceptable salts thereof, a preparation method of the 2-(piperidinyl) pyridazinone compound, a pharmaceutical composition of the 2-(piperidinyl) pyridazinone compound and application of the 2-(piperidinyl) pyridazinone compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

Provided herein are methods of nerve blockage, for example for treatment of obesity, heart failure, cardiovascular disease, muscle spasms, chronic pain, or urinary retention in a patient. The method comprises first heating a nerve above physiological temperature (e.g., 37° C. in a human), such as from 43° C. to 54° C. for a duration that leads to reversible nerve blockage as opposed to nerve damage. Second, reversible nerve blockage is produced by cooling the nerve below physiological temperature to a temperature in which reversible nerve blockage is achieved, for example from 15° C. to 30° C.

The invention provides a traditional Chinese medicine compound composition with a nerve repairing effect, a cell culture medium, a traditional Chinese medicine-neural stem cell exosome compound and application, and belongs to the technical field of biological medicine. Based on the basic theory of traditional Chinese medicine and the combined theory of traditional Chinese medicine and western medicine, the traditional Chinese medicine compound composition is provided and comprises gastrodia elata exosomes, astragalus membranaceus exosomes and resveratrol, the traditional Chinese medicine compound composition is prepared into a cell culture medium, neural stem cells are cultured through the cell culture medium, and the neural stem cells are obtained. Therefore, the traditional Chinese medicine-neural stem cell exosome compound with an efficient nerve repairing function is prepared. The traditional Chinese medicine-neural stem cell exosome compound achieves the purpose of comprehensively repairing nerve injury by precisely targeting nerve cells, promoting neurogenesis, repairing the function of a neural circuit and reducing the inflammatory effect, and can be used for preparing related medical instruments and drugs for nerve repair.

The invention belongs to the field of biological medicine, and relates to application of a TRPV4 inhibitor in preparation of a medicine for preventing or treating diseases caused by trimethyltin chloride poisoning. The TRPV4 ion channel inhibitor can remarkably prolong the incubation period of epilepsy caused by trimethyltin chloride poisoning, relieve the severity of epileptic seizure, improve nerve injury and increase the survival rate. Therefore, a new drug target is provided for diagnosis of trimethyltin chloride poisoning and drug research and development, and a new strategy is provided for clinical treatment of trimethyltin chloride poisoning.

The application of the autologous dendritic cell in preparation of the medicine for treating the nerve injury erectile dysfunction can well promote recovery of the erectile function, perform staged reinfusion, induce immune regulation, repair nerve and blood vessel functions and improve a sex hormone regulation pathway. And the autologous dendritic cells are derived from a user, and have the advantages of safety, effectiveness and convenience in use. The combined immune cell therapy is obviously superior to a single treatment path in efficacy, is also more suitable for chronic, non-structural, subclinical and other ED people which are difficult to intervene by traditional methods, and has stronger individual adaptation ability and long-term controllability at the same time. Compared with a traditional scheme, the cell therapy targeting is better, and the treatment effect is faster.

The invention relates to the technical field of functional food, health care products and medicines, in particular to a composition for neuroprotection and cognitive function improvement and a preparation method and application thereof. The invention provides a composition for neuroprotection and cognitive function improvement. The composition is prepared from calcium beta-hydroxy-beta-methylbutyrate, nervonic acid and menthol, by compounding the calcium beta-hydroxy-beta-methylbutyrate, nervonic acid and menthol, the compound has a synergistic effect and can be applied to preparation of food, health care products or medicines for protecting nerves, delaying nerve aging, improving learning and memory ability, repairing nerve injury and preventing or assisting in treating neurodegenerative diseases.

The invention relates to the field of medicine, in particular to a preparation method of biphenyl tetrazole derivatives and application of the biphenyl tetrazole derivatives in preparation, prevention or treatment of neurodegenerative diseases and related diseases caused by plateau hypoxia, and the structure of the biphenyl tetrazole derivatives is shown as a formula 8 X in the specification, and R3 is selected from hydrogen, fluorine, chlorine, iodine, methyl, methoxyl, dimethylamino, trifluoromethyl, hydroxyl, carboxyl, nitryl, methoxycarbonyl, acrylate and acrylamide. The biphenyl tetrazole derivative prepared in the invention can destroy Nrf2-Keap1 protein-protein interaction (PPI), and has a very good protection effect on tested cell models of hydrogen peroxide and 6-hydroxydopamine nerve injury and cobalt chloride hypoxia injury. Experimental data show that the biphenyl tetrazole derivative disclosed by the invention is a potential therapeutic molecule, and a certain basis is provided for research and development of drugs.

Disclosed are an aromatic alkylamine ferroptosis inhibitor based on a butylphthalide structure, a preparation method therefor, and an application thereof. The chemical structural formula of the ferroptosis inhibitor is as shown in formula (1) or formula (2). The ferroptosis inhibitor is capable of inhibiting ferroptosis caused by a ferroptosis inducer, and reduces the level of intracellular reactive oxygen species. The ferroptosis inhibitor reduces neurological damage caused by cerebral ischemia-reperfusion, and alleviates symptoms of neurological disorders such as Alzheimer's disease and Parkinson's disease. Compared to the ferroptosis inhibitor Ferrostatin-1, the arylalkylamine compound exhibits better metabolic stability and is suitable for in-vivo efficacy evaluation. Therefore, the novel arylalkylamine compound provided by the present invention demonstrates great application value in the treatment of ferroptosis-related neurological disorders.

The present invention relates to the field of nutraceuticals, specifically to a synergistic bioactive composition designed to improve joint health. This composition comprises Palmitoylethanolamide (PEA) and Cucumis sativus, aimed at reducing joint pain and protecting cartilage. It addresses the complex pain components of osteoarthritis, including both nociceptive pain, which stems from ongoing joint inflammation and tissue damage, and neuropathic pain, which indicates nerve damage. This nutraceutical composition provides a novel solution for mitigating the debilitating effects of osteoarthritis through oral administration, utilizing pharmaceutically acceptable excipients to ensure efficacy and safety.

Methods and compositions for preventing and / or treating nerve damage, e.g., nerve damage associated with diabetic polyneuropathy, are provided herein. The methods comprise administering ASK, a cocktail of transcription factors, to the subject, which maintains or increases sensation. The presently disclosed subject matter further comprises methods and compositions for transplanting skin tissue administered with ASK.

The application belongs to the field of animal model construction, and particularly relates to a brain protein induced lung edema animal model after brain injury and a construction method and application thereof. The construction method comprises the following steps: injecting brain protein into a rat to construct. The brain protein induced lung edema animal model after brain injury can simulate lung edema caused by brain protein leakage after brain injury, and avoids lung edema induced by sympathetic nerve excitation caused by nerve injury. The prepared animal model has the advantages of good stability, good repeatability and long survival time.

The invention relates to a phosphatidylserine derivative with high neuroprotective activity and application of the phosphatidylserine derivative in treatment of Alzheimer's disease and Parkinson's disease. Specifically, the present invention provides a compound of formula I, or a tautomer, a stereoisomer, or a pharmaceutically acceptable salt thereof, in which the definitions of each group and substituent are described in the specification and claims. The invention further provides a preparation method of the compound, and the novel phosphatidylserine derivative which has good nerve cell proliferation promoting activity, nerve injury protection activity and the like and can be used for preparing drugs for preventing and / or treating neurodegenerative diseases.

An arylalkylamine ferroptosis inhibitor based on an edaravone structure, and a preparation method therefor and a use thereof. The structural formula of the ferroptosis inhibitor is as shown in the following formula I, formula II, or formula III: formula I, formula II, formula III. The ferroptosis inhibitor has strong ROS scavenging ability and an inhibitory effect on lipid peroxidation, can inhibit ferroptosis caused by an ferroptosis inducer, and can reduce cerebral ischemia and nerve damage caused by cerebral ischemia, and alleviate symptoms of neurological diseases such as Parkinson's syndrome. On the basis of the ferrostain-1 / edaravone structure, the provided arylalkylamine ferroptosis inhibitor can exert a synergistic effect by means of multiple effects to treat ferroptosis-related diseases and can also expand the use of edaravone, thereby providing a candidate compound for subsequent drug research and development.

A polypeptide derivative or a pharmaceutically acceptable salt thereof, through the introduction of fatty acid side chains at specific sites of the ISP polypeptide, and / or the formation of a cyclic structure within the polypeptide by generating amide bonds between E and K, significantly improves the stability and activity of the resulting polypeptide derivative. This allows for better preparation of drugs for treating diseases related to nerve damage.

This invention provides the application of *Bifidobacterium animalis* subsp. lactis CP-9 in the preparation of compositions that promote neurodevelopment and alleviate cognitive impairment and nerve damage. This invention discovers that *Bifidobacterium animalis* subsp. lactis CP-9 can improve abnormal neurodevelopment, cognitive impairment, and nerve damage, and has a protective effect on the nervous system and overall health. This novel application expands the application scope of *Bifidobacterium animalis* subsp. lactis as a probiotic, and is of great significance for further exploring the functions of probiotics and developing probiotics with higher nutritional and health benefits. It also opens up new avenues and solutions for protecting nervous system health and preventing nervous system diseases through dietary strategies.

This invention discloses an injectable hydrogel for long-term sustained release of NGF and CNTF, its preparation method, and its application in visual system diseases. The bioactive factor sustained-release hydrogel of this invention comprises a hydrogel matrix and bioactive factor microspheres loaded on the matrix; the raw materials for preparing the hydrogel matrix include chitosan, type II collagen, and hyaluronic acid; the bioactive factor microspheres comprise an inner core and a capsule wall, the inner core being a bioactive factor selected from one or both of ciliary neurotrophic factor and nerve growth factor, and the capsule wall being a polylactic acid-glycolic acid copolymer. This hydrogel can achieve long-term stable release of NTF, activating endogenous neural stem cells in the retina to generate new retinal ganglion cells. It exhibits high safety, good injectability, and a long sustained-release period, and can be used to prepare drugs for treating visual system diseases such as glaucoma, optic nerve damage, and macular degeneration.

The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.